236 related articles for article (PubMed ID: 34818873)
21. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
Michiels JJ; Berneman ZN; van der Planken M; Schroyens W; Budde U; van Vliet HH
Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
[TBL] [Abstract][Full Text] [Related]
22. Potent and rapid reversal of the von Willebrand factor inhibitor aptamer BT200.
Zhu S; Gilbert JC; Liang Z; Kang D; Li M; Tarantino PM; Jilma B
J Thromb Haemost; 2020 Jul; 18(7):1695-1704. PubMed ID: 32275107
[TBL] [Abstract][Full Text] [Related]
23. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease.
Jilma B; Paulinska P; Jilma-Stohlawetz P; Gilbert JC; Hutabarat R; Knöbl P
Thromb Haemost; 2010 Sep; 104(3):563-70. PubMed ID: 20589313
[TBL] [Abstract][Full Text] [Related]
24. Acquired von Willebrand disease--hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin, and continuous factor concentrate infusion.
Frank RD; Kunz D; Wirtz DC
Am J Hematol; 2002 May; 70(1):64-71. PubMed ID: 11994985
[TBL] [Abstract][Full Text] [Related]
25. von Willebrand's disease: use of collagen binding assay provides potential improvement to laboratory monitoring of desmopressin (DDAVP) therapy.
Favaloro EJ; Dean M; Grispo L; Exner T; Koutts J
Am J Hematol; 1994 Mar; 45(3):205-11. PubMed ID: 8296790
[TBL] [Abstract][Full Text] [Related]
26. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
Deitcher SR; Tuller J; Johnson JA
Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955
[TBL] [Abstract][Full Text] [Related]
27. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
[TBL] [Abstract][Full Text] [Related]
28. Von Willebrand disease: pathogenesis and management.
Rodeghiero F
Thromb Res; 2013 Jan; 131 Suppl 1():S47-50. PubMed ID: 23452742
[TBL] [Abstract][Full Text] [Related]
29. von Willebrand Factor Predicts Mortality in ACS Patients Treated with Potent P2Y12 Antagonists and is Inhibited by Aptamer BT200 Ex Vivo.
Kovacevic KD; Jilma B; Zhu S; Gilbert JC; Winter MP; Toma A; Hengstenberg C; Lang I; Kubica J; Siller-Matula JM
Thromb Haemost; 2020 Sep; 120(9):1282-1290. PubMed ID: 32679592
[TBL] [Abstract][Full Text] [Related]
30. The von Willebrand factor-binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A.
Ay C; Kovacevic KD; Kraemmer D; Schoergenhofer C; Gelbenegger G; Firbas C; Quehenberger P; Jilma-Stohlawetz P; Gilbert JC; Zhu S; Beliveau M; Koenig F; Iorio A; Jilma B; Derhaschnig U; Pabinger I
Blood; 2023 Mar; 141(10):1147-1158. PubMed ID: 36108308
[TBL] [Abstract][Full Text] [Related]
31. Laboratory diagnosis and molecular basis of mild von Willebrand disease type 1.
Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van Vliet HH
Acta Haematol; 2009; 121(2-3):85-97. PubMed ID: 19506353
[TBL] [Abstract][Full Text] [Related]
32. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease.
Ruggeri ZM; Pareti FI; Mannucci PM; Ciavarella N; Zimmerman TS
N Engl J Med; 1980 May; 302(19):1047-51. PubMed ID: 6767976
[TBL] [Abstract][Full Text] [Related]
33. Characterization of a myeloma patient with a life-threatening hemorrhagic diathesis: presence of a lambda dimer protein inhibiting shear-induced platelet aggregation by binding to the A1 domain of von Willebrand factor.
Shinagawa A; Kojima H; Berndt MC; Kaneko S; Suzukawa K; Hasegawa Y; Shigeta O; Nagasawa T
Thromb Haemost; 2005 May; 93(5):889-96. PubMed ID: 15886805
[TBL] [Abstract][Full Text] [Related]
34. Changes in factor VIII binding capacity of von Willebrand factor and factor VIII coagulant activity in two patients with type 2N von Willebrand disease after hemostatic treatment and during pregnancy.
Nishino M; Nishino S; Sugimoto M; Shibata M; Tsuji S; Yoshioka A
Int J Hematol; 1996 Aug; 64(2):127-34. PubMed ID: 8854570
[TBL] [Abstract][Full Text] [Related]
35. The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study.
Kessler CM; Friedman K; Schwartz BA; Gill JC; Powell JS;
Thromb Haemost; 2011 Aug; 106(2):279-88. PubMed ID: 21725579
[TBL] [Abstract][Full Text] [Related]
36. Von Willebrand factor in the vessel wall mediates platelet adherence.
Stel HV; Sakariassen KS; de Groot PG; van Mourik JA; Sixma JJ
Blood; 1985 Jan; 65(1):85-90. PubMed ID: 3917314
[TBL] [Abstract][Full Text] [Related]
37. N1421K mutation in the glycoprotein Ib binding domain impairs ristocetin- and botrocetin-mediated binding of von Willebrand factor to platelets.
Lanke E; Kristoffersson AC; Isaksson C; Holmberg L; Lethagen S
Eur J Haematol; 2008 Nov; 81(5):384-90. PubMed ID: 18637125
[TBL] [Abstract][Full Text] [Related]
38. Patients with severe von Willebrand disease are insensitive to the releasing effect of DDAVP: evidence that the DDAVP-induced increase in plasma factor VIII is not secondary to the increase in plasma von Willebrand factor.
Cattaneo M; Simoni L; Gringeri A; Mannucci PM
Br J Haematol; 1994 Feb; 86(2):333-7. PubMed ID: 8199023
[TBL] [Abstract][Full Text] [Related]
39. Perhaps it's not the platelet: Ristocetin uncovers the potential role of von Willebrand factor in impaired platelet aggregation following traumatic brain injury.
Kornblith LZ; Robles AJ; Conroy AS; Hendrickson CM; Calfee CS; Fields AT; Callcut RA; Cohen MJ
J Trauma Acute Care Surg; 2018 Nov; 85(5):873-880. PubMed ID: 29985231
[TBL] [Abstract][Full Text] [Related]
40. Von Willebrand's disease: case report and review of literature.
Echahdi H; El Hasbaoui B; El Khorassani M; Agadr A; Khattab M
Pan Afr Med J; 2017; 27():147. PubMed ID: 28904675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
